131747-68-7

Basic information

• Product Name: 2-Pyridinecarbonitrile,5-formyl-(9CI)
• Synonyms: 2-Pyridinecarbonitrile,5-formyl-(9CI);5-formylpyridine-2-carbonitrile;5-ForMylpicolinonitrile;5-ForMyl-2-pyridinecarbonitrile;5-forMylpyridin-2-carbonitrile;6-Cyanopyridine-3-carboxaldehyde;5-ForMyl-2-pyridinecarbonitrile, 95+%
• CAS NO: 131747-68-7
• Molecular Formula: C₇H₄N₂O
• Molecular Weight: 132.122
• Product Categories: PYRIDINE;Heterocycle-Pyridine series
• Mol File: 131747-68-7.mol

Chemical Properties

• Boiling Point: 331.3±27.0 °C(Predicted)
• Appearance: /
• Density: 1.24±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: Chloroform, Methanol
• PKA: -2.12±0.10(Predicted)
• CAS DataBase Reference: 2-Pyridinecarbonitrile,5-formyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyridinecarbonitrile,5-formyl-(9CI)(131747-68-7)
• EPA Substance Registry System: 2-Pyridinecarbonitrile,5-formyl-(9CI)(131747-68-7)

Safety Data

• Hazardous Substances Data: 131747-68-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Pyridinecarbonitrile,5-formyl-(9CI) is used as a key intermediate in the synthesis of pharmaceutical compounds for the treatment of various diseases. One such application is in the production of GLPG0634 (C982190), a drug used for the treatment of rheumatoid arthritis. Its unique structure allows for the development of novel therapeutic agents that can target specific biological pathways and provide relief from the symptoms of the disease.

Upstream product

• 58553-48-3 5-(hydroxymethyl)pyridine-2-carbonitrile 
• 79-37-8 oxalyl dichloride 
• 149806-06-4 6-bromonicotinaldehyde 
• 220904-17-6 2-bromo-5-[1,3]dioxolan-2-yl-pyridine 
• 671776-91-3 5-(1,3-dioxolan-2-yl)-2-cyano-pyridine 
• 114951-34-7 3-Acetoxymethylpyridine-N-oxide 
• 131747-37-0 3-Acetoxymethyl-6-cyanopyridine 

Downstream Products

• 675103-35-2 5-{5-acetyl-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-4-yl}pyridine-2-carbonitrile 

Relevant articles and documents

Versatility of Terpyridine-Functionalised Aryl Tetrazoles: Photophysical Properties, Ratiometric Sensing of Zinc Cations and Sensitisation of Lanthanide Luminescence

Four new tetrazole-containing species, in conjugation with terpyridine moieties through phenyl or pyridyl linkers, have been synthesised and characterised. In the series, the tetrazole functional groups are either in their acidic form or are alkylated at the N2 position with a methyl group. The photophysical properties of the species reveal moderate UV or efficient blue fluorescent emission, with photoluminescence quantum yields of around 30 % and 80 % for UV and blue emission, respectively. The spectral profiles can be reversibly modulated through protonation/deprotonation, with changes being consistent with an increase of the electron density on the tetrazole rings upon deprotonation or a decrease of the electron density on the terpyridines through protonation. The tetrazole-containing species were also investigated for fluorescence sensing of biologically and environmentally important metal ions, highlighting a ratiometric response to the presence of Zn2+. Furthermore, this ratiometric response could be well discriminated from that of interfering Cd2+ ions. Lastly, the species have been investigated as ligands for Eu3+ and Yb3+ cations, revealing efficient sensitisation, to give typical red and near-infrared emissions, respectively.

As neuroprotective agents of pharmaceutical compounds

The invention discloses a medicinal compound as a neuroprotective agent. The medicinal compound is a neuronal nitric oxide synthase-postsynaptic density protein 95 (nNOS-PSD95) decoupling agent. The medicinal compound is a benzene ring derivative shown in the general formula (I) or its pharmaceutically acceptable salt. The invention further discloses a preparation method of the medicinal compound and a use of the medicinal compound in prevention and treatment on neuronal damage influence-caused diseases.

CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): wherein variables A4, A5, A6, A8, and each of Ra, Rb, R1, R2, R3 and R7 of Formula (I), independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and 15 deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimers Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas (II) and (III), and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.

BRIDGED BICYCLIC AMINO THIAZINE DIOXIDE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, R1, R2, R3, R7 and n of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, compounds of Formula III, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III, and sub-Formulas thereof.

Iminothiadiazine Dioxide Compounds as BACE Inhibitors, Compositions and Their Use

In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R1, R2, R3, R4, R5, R9, ring A, ring B, m, n, p, -L1-, -L2-, and -L3- is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (“Aβ”) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimer's disease, are also disclosed.

Antiprotozoal activity of dicationic 3,5-diphenylisoxazoles, their prodrugs and aza-analogues

Fifty novel prodrugs and aza-analogues of 3,5-bis(4-amidinophenyl)isoxazole and its derivatives were prepared. Eighteen of the 24 aza-analogues exhibited IC50 values below 25 nM against Trypanosoma brucei rhodesiense or Plasmodium falciparum. S

AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, R1, R2, R3, R7 and n of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-II.

FUSED MULTI-CYCLIC SULFONE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A5, A6, A8, R1, R2, R3, R7, X, Y, n and o of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, compounds of Formula III, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III, and sub-Formulas thereof.

PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, each of R1 and R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III.

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE ABSTRACT OF THE DISCLOSURE The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: {INSERT STRUCTURE HERE} I wherein variables A4, A5, A6, A8, each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.